# Claim table — AI longevity Short

| Claim | Evidence label |
|---|---|
| “Scientists figured out how to reverse aging using AI.” | Overstated. The real story is AI-assisted protein-engineering research aimed at improving cellular reprogramming markers in lab cells. |
| Yamanaka factors are real and Nobel-linked. | Supported. The 2012 Nobel Prize recognized Gurdon and Yamanaka for discoveries that mature cells can be reprogrammed to become pluripotent. |
| OpenAI and Retro Biosciences used GPT-4b micro for Yamanaka-factor protein engineering. | Supported. OpenAI describes GPT-4b micro as a specialized model for protein engineering in collaboration with Retro Bio. |
| The work achieved “50×” improvement. | Partly supported but needs precision. OpenAI reports greater than 50-fold higher expression of stem-cell reprogramming markers than wild-type controls; MIT Technology Review described this as preliminary measures before publication. |
| 30% of 50-year-old donor cells repaired/reprogrammed in seven days. | Partly supported but phrased too casually in the Short. OpenAI reports that MSCs from three middle-aged donors over 50 began expressing key pluripotency markers within 7 days; this is not the same as a human therapy reversing age. |
| People will soon take a shot that literally reverses cellular age. | Not established. The source record points to preclinical lab work, safety questions, delivery/regulatory hurdles and no approved consumer anti-aging injection. |
| Stem-cell/regenerative medicine products are safe to buy/use now for aging. | Not supported. FDA warns many regenerative-medicine products are illegally marketed and can carry risks including tumor formation, infections, blindness and neurologic events. |
| The Short MP4 was locally captured. | Not supported. Metadata, description, captions and thumbnail were captured; YouTube blocked MP4 download with HTTP 403, so the article embeds the public YouTube Short. |